At Precision, we utilize a proprietary genome editing method we call ARCUS combined with a team made up of some of the leading minds and pioneers in genome editing in an effort to overcome cancers, cure genetic diseases, and enable the development of safer, more productive food sources.
Genome editing technologies allow us to rethink our approach to a broad array of serious challenges faced by the world today. We now have the ability to precisely edit the DNA of a living organism, opening up the possibility of correcting genetic problems at their source.
The decade long march to success
Precision Biosciences was founded in 2006 by then-Fuqua student Matt Kane alongside postdoctoral fellows Derek Jantz and Jeff Smith. This team of “Precisioneers” has spent the last decade developing and applying their proprietary ARCUS genome-editing platform “in an effort to overcome cancers, cure genetic diseases, and enable the development of safer, more productive food sources.” Their success has been fueled by a successful Series A round in 2015, and a development deal with Baxalta (now Shire) potentially worth upwards of $1.6 B in payments and milestones (at the time, the largest gene therapy deal ever in immuno-oncology). For more, read:
Image: Matthew Kane, CEO, Co-founder.